Rivastigmine prevention of delirium
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Delirium
Conditions
Delirium
Trial Timeline
Jan 1, 2006 → Jul 1, 2007
NCT ID
NCT00257868About Rivastigmine prevention of delirium
Rivastigmine prevention of delirium is a phase 3 stage product being developed by Novartis for Delirium. The current trial status is completed. This product is registered under clinical trial identifier NCT00257868. Target conditions include Delirium.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00257868 | Phase 3 | Completed |
Competing Products
17 competing products in Delirium
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lemborexant 5 mg + Control (placebo) group | Eisai | Phase 2 | 52 |
| Suvorexant + Placebo | Merck | Phase 3 | 77 |
| Suvorexant 20 mg + Placebo | Merck | Phase 2 | 52 |
| Rivastigmine + Placebo | Novartis | Approved | 85 |
| Rivastigmine transdermal patch + placebo patch | Novartis | Phase 3 | 77 |
| Rivastigmine Patch | Novartis | Approved | 85 |
| Dexmedetomidine + Placebo | Pfizer | Phase 3 | 76 |
| Parecoxib | Pfizer | Approved | 84 |
| Dexmedetomidine + Placebo | Pfizer | Phase 3 | 76 |
| Pregabalin | Pfizer | Phase 3 | 76 |
| Dexmedetomidine + Midazolam | Pfizer | Phase 3 | 76 |
| Propofol + Dexmedetomidine | Pfizer | Pre-clinical | 22 |
| Dexmedetomidine + Saline placebo | Pfizer | Phase 2/3 | 64 |
| Cyclopofol + Propofol | Haisco Pharmaceutical Group | Approved | 82 |
| Dexmedetomidine + Sodium chloride 0.9% | Baxter | Phase 3 | 74 |
| Dexmedetomidine Hydrochloride Group | Brain Biotech | Approved | 77 |
| Dexmedetomidine sublingual film | BioXcel Therapeutics | Phase 2 | 44 |